Roy Buchanan
Stock Analyst at JMP Securities
(0.78)
# 1,611
Out of 4,654 analysts
40
Total ratings
27.03%
Success rate
-22.92%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Reiterates: Market Outperform | $22 | $9.53 | +130.85% | 10 | Oct 9, 2024 | |
| CVAC CureVac | Reiterates: Market Outperform | $16 | $2.54 | +529.92% | 7 | Sep 16, 2024 | |
| HOOK HOOKIPA Pharma | Maintains: Market Outperform | $23 → $24 | $3.00 | +700.00% | 1 | Aug 9, 2024 | |
| ANTX AN2 Therapeutics | Maintains: Market Outperform | $6 → $3 | $1.00 | +200.00% | 4 | Aug 9, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Market Outperform | $4 → $5 | $3.64 | +37.36% | 5 | Aug 2, 2024 | |
| INO Inovio Pharmaceuticals | Initiates: Market Outperform | $12 | $4.27 | +181.36% | 1 | Jan 4, 2024 | |
| DVAX Dynavax Technologies | Maintains: Market Outperform | $25 → $27 | $12.21 | +121.13% | 5 | Nov 3, 2023 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $15 | $2.12 | +607.55% | 1 | Mar 6, 2023 | |
| ARGX argenx SE | Maintains: Market Outperform | $443 → $448 | $564.23 | -20.60% | 2 | Mar 3, 2023 | |
| CRMD CorMedix | Maintains: Market Perform | $14 → $16 | $10.33 | +54.89% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.28 | - | 2 | Feb 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $420 | $3.55 | +11,730.99% | 1 | Sep 14, 2021 |
Enanta Pharmaceuticals
Oct 9, 2024
Reiterates: Market Outperform
Price Target: $22
Current: $9.53
Upside: +130.85%
CureVac
Sep 16, 2024
Reiterates: Market Outperform
Price Target: $16
Current: $2.54
Upside: +529.92%
HOOKIPA Pharma
Aug 9, 2024
Maintains: Market Outperform
Price Target: $23 → $24
Current: $3.00
Upside: +700.00%
AN2 Therapeutics
Aug 9, 2024
Maintains: Market Outperform
Price Target: $6 → $3
Current: $1.00
Upside: +200.00%
Arbutus Biopharma
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $3.64
Upside: +37.36%
Inovio Pharmaceuticals
Jan 4, 2024
Initiates: Market Outperform
Price Target: $12
Current: $4.27
Upside: +181.36%
Dynavax Technologies
Nov 3, 2023
Maintains: Market Outperform
Price Target: $25 → $27
Current: $12.21
Upside: +121.13%
Esperion Therapeutics
Mar 6, 2023
Reiterates: Market Outperform
Price Target: $15
Current: $2.12
Upside: +607.55%
argenx SE
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $564.23
Upside: -20.60%
CorMedix
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $10.33
Upside: +54.89%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $2.28
Upside: -
Sep 14, 2021
Initiates: Market Outperform
Price Target: $420
Current: $3.55
Upside: +11,730.99%